Figueroa JD 1 , Middlebrooks CD 2 , Banday AR 2 , Ye Y 3 , Garcia-Closas M 4 , Chatterjee N 2 Show all authors , Koutros S 2 , Kiemeney LA 5 , Rafnar T 6 , Bishop T 7 , Furberg H 8 , Matullo G 9 , Golka K 10 , Gago-Dominguez M 11 , Taylor JA 12 , Fletcher T 13 , Siddiq A 14 , Cortessis VK 15 , Kooperberg C 16 , Cussenot O 17 , Benhamou S 18 , Prescott J 19 , Porru S 20 , Dinney CP 21 , Malats N 22 , Baris D 2 , Purdue MP 2 , Jacobs EJ 23 , Albanes D 2 , Wang Z 24 , Chung CC 25 , Vermeulen SH 5 , Aben KK 5 , Galesloot TE 5 , Thorleifsson G 6 , Sulem P 6 , Stefansson K 26 , Kiltie AE 27 , Harland M 7 , Teo M 28 , Offit K 29 , Vijai J 29 , Bajorin D 30 , Kopp R 31 , Fiorito G 9 , Guarrera S 9 , Sacerdote C 32 , Selinski S 10 , Hengstler JG 10 , Gerullis H 33 , Ovsiannikov D 34 , Blaszkewicz M 10 , Castelao JE 35 , Calaza M 36 , Martinez ME 37 , Cordeiro P 38 , Xu Z 39 , Panduri V 12 , Kumar R 40 , Gurzau E 41 , Koppova K 42 , Bueno-De-Mesquita HB 43 , Ljungberg B 44 , Clavel-Chapelon F 45 , Weiderpass E 46 , Krogh V 47 , Dorronsoro M 48 , Travis RC 49 , Tjønneland A 50 , Brennan P 51 , Chang-Claude J 40 , Riboli E 14 , Conti D 52 , Stern MC 52 , Pike MC 7 , Van Den Berg D 52 , Yuan JM 53 , Hohensee C 16 , Jeppson RP 16 , Cancel-Tassin G 54 , Roupret M 55 , Comperat E 56 , Turman C 57 , De Vivo I 58 , Giovannucci E 59 , Hunter DJ 60 , Kraft P 61 , Lindstrom S 57 , Carta A 20 , Pavanello S 62 , Arici C 20 , Mastrangelo G 62 , Kamat AM 21 , Zhang L 3 , Gong Y 3 , Pu X 3 , Hutchinson A 24 , Burdett L 24 , Wheeler WA 63 , Karagas MR 64 , Johnson A 65 , Schned A 64 , Monawar Hosain GM 66 , Schwenn M 67 , Kogevinas M 68 , Tardón A 69 , Serra C 70 , Carrato A 71 , García-Closas R 72 , Lloreta J 73 , Andriole G 74 , Grubb R 74 , Black A 2 , Diver WR 23 , Gapstur SM 23 , Weinstein S 2 , Virtamo J 75 , Haiman CA 76 , Landi MT 2 , Caporaso NE 2 , Fraumeni JF 2 , Vineis P 77 , Wu X 3 , Chanock SJ 2 , Silverman DT 2 , Prokunina-Olsson L 2 , Rothman N 2

Affiliations 

  • 1 Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA, Usher Institute of Population Health Sciences and Informatics, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK, jonine.figueroa@ed.ac.uk
  • 2 Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
  • 3 Department of Epidemiology, MD Anderson Cancer Center, Houston, TX, USA
  • 4 Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA, Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK
  • 5 Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
  • 6 deCODE Genetics/Amgen, Inc., Reykjavik, Iceland
  • 7 Section of Epidemiology and Biostatistics
  • 8 Department of Epidemiology and Biostatistics
  • 9 Department of Medical Sciences, University of Turin, Turin, Italy, Human Genetics Foundation, Turin, Italy
  • 10 Leibniz Research Centre for Working Environment and Human Factors, Dortmund, Germany
  • 11 Genomic Medicine Group, Galician Foundation of Genomic Medicine, Servicio Galego de Saude (SERGAS), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain
  • 12 Epidemiology Branch, National Institute of Environmental Health Sciences (NIEHS), Epigenetic and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), Research Triangle Park, NC, USA
  • 13 London School of Hygiene and Tropical Medicine, London, UK
  • 14 School of Public Health
  • 15 Department of Preventive Medicine, USC Keck School of Medicine, Department of Obstetrics and Gynecology, Norris Comprehensive Cancer Center, USC Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
  • 16 Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  • 17 Department of Urology, Tenon, Centre de Recherche sur les Pathologies Prostatiques, Paris, France, UPMC Univ Paris 06, GRC n°5, ONCOTYPE-URO, Paris, France
  • 18 Institut national de la sante et de la recherche medicale, U946, Foundation Jean Dausset Centre d'Etude du Polymorphisme Humain (CEPH), Paris, France, Centre National de la Receherche Scientifique, UMR8200, Institut Gustave-Roussy, Villejuif, France
  • 19 Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Department of Epidemiology
  • 20 Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy
  • 21 Department of Urology, MD Anderson Cancer Center, Houston, TX, USA
  • 22 Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
  • 23 Epidemiology Research Program, American Cancer Society, Atlanta, GA, USA
  • 24 Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, MD, USA
  • 25 Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA, Department of Urology, MD Anderson Cancer Center, Houston, TX, USA
  • 26 deCODE Genetics/Amgen, Inc., Reykjavik, Iceland, Faculty of Medicine, University of Iceland, Reykjavik, Iceland
  • 27 CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK
  • 28 Radiotherapy Research Group, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds LS9 7TF, UK
  • 29 Department of Medicine
  • 30 Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine
  • 31 Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
  • 32 Cancer Epidemiology, CPO Piemonte, Turin, Italy
  • 33 University Hospital for Urology, Klinikum Oldenburg, School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Oldenburg, Germany, Department of Urology, Lukasklinik Neuss, Germany
  • 34 Department of Urology, St. Josefs Hospital, Dortmund-Hörde, Germany
  • 35 Oncology and Genetics Unit, Complejo Hospitalario, Instituto de Investigacion Biomedica (IBI) Orense-Pontevedra-Vigo, Xerencia de Xestion Integrada de Vigo-SERGAS, Vigo, Spain
  • 36 Genomic Medicine Group, Galician Foundation of Genomic Medicine, Servicio Galego de Saude (SERGAS), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, Galicia, Spain
  • 37 Department of Family Medicine and Public Health, Moores Cancer Center, University of California San Diego, San Diego, CA, USA
  • 38 Department of Urology, Complejo Hospitalario, University of Santiago de Compostela, Servicio Galego de Saude (SERGAS), Santiago de Compostela, Spain
  • 39 Epidemiology Branch, National Institute of Environmental Health Sciences (NIEHS)
  • 40 Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Baden-Württemberg; University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
  • 41 Environmental Health Center, Cluj, Romania
  • 42 State Health Institute, Banska Bystrica, Slovakia
  • 43 School of Public Health, Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands, Department of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 44 Department of Surgical and Perioperative Sciences, Urology and Andrology, Umea University, Umea, Sweden
  • 45 Inserm, Centre for research in Epidemiology and Population Health (CESP), U1018, Nutrition, Hormones and Women's Health team, Villejuif F-94805, France, Université Paris Sud, UMRS 1018, Villejuif F-94805, France, Institut Gustave Roussy, Villejuif F-94805, France
  • 46 Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway, Genetic Epidemiology Group, Folkhälsan Research Center, Helsinki, Finland
  • 47 Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
  • 48 Health Department, BioDonostia Research Institute, Basque Region, Spain, Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
  • 49 Cancer Epidemiology Unit, University of Oxford, Oxford, UK
  • 50 Danish Cancer Society Research Center, Copenhagen, Denmark
  • 51 International Agency for Research on Cancer (IARC), Lyon, France
  • 52 School of Public Health, Department of Obstetrics and Gynecology
  • 53 University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
  • 54 Centre de Recherche sur les Pathologies Prostatiques, Paris, France, UPMC Univ Paris 06, GRC n°5, ONCOTYPE-URO, Paris, France
  • 55 Department of Urology, Pitié-Salpétrière, Centre de Recherche sur les Pathologies Prostatiques, Paris, France, UPMC Univ Paris 06, GRC n°5, ONCOTYPE-URO, Paris, France
  • 56 Department of Pathology, Pitié-Salpétrière, Assistance-Publique Hôpitaux de Paris (APHP), Paris, France, Centre de Recherche sur les Pathologies Prostatiques, Paris, France, UPMC Univ Paris 06, GRC n°5, ONCOTYPE-URO, Paris, France
  • 57 Department of Epidemiology
  • 58 Norris Comprehensive Cancer Center, USC Keck School of Medicine, University of Southern California, Los Angeles, CA, USA, Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
  • 59 Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Department of Epidemiology, Department of Nutrition
  • 60 Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Department of Epidemiology, Department of Nutrition, Broad Institute of Harvard and MIT, Cambridge, MA, USA
  • 61 Department of Epidemiology, Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA
  • 62 Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy
  • 63 Information Management Services, Silver Spring, MD, USA
  • 64 Geisel School of Medicine, Dartmouth College, Hanover, NH, USA
  • 65 Vermont Cancer Registry, Burlington, VT, USA
  • 66 New Hampshire State Cancer Registry, Concord, NH, USA
  • 67 Maine Cancer Registry, Augusta, ME, USA
  • 68 Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, Municipal Institute of Medical Research, (IMIM-Hospital del Mar), Barcelona, Spain, National School of Public Health, Athens, Greece
  • 69 Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain, Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain
  • 70 Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain, Municipal Institute of Medical Research, (IMIM-Hospital del Mar), Barcelona, Spain, Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain
  • 71 Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain
  • 72 Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain
  • 73 Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
  • 74 Division of Urologic Surgery, Washington University School of Medicine, Saint Louis, MO, USA and
  • 75 Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland
  • 76 Department of Obstetrics and Gynecology
  • 77 Human Genetics Foundation, Turin, Italy, MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London, UK
Hum. Mol. Genet., 2016 Mar 15;25(6):1203-14.
PMID: 26732427 DOI: 10.1093/hmg/ddv492

Abstract

Candidate gene and genome-wide association studies (GWAS) have identified 15 independent genomic regions associated with bladder cancer risk. In search for additional susceptibility variants, we followed up on four promising single-nucleotide polymorphisms (SNPs) that had not achieved genome-wide significance in 6911 cases and 11 814 controls (rs6104690, rs4510656, rs5003154 and rs4907479, P < 1 × 10(-6)), using additional data from existing GWAS datasets and targeted genotyping for studies that did not have GWAS data. In a combined analysis, which included data on up to 15 058 cases and 286 270 controls, two SNPs achieved genome-wide statistical significance: rs6104690 in a gene desert at 20p12.2 (P = 2.19 × 10(-11)) and rs4907479 within the MCF2L gene at 13q34 (P = 3.3 × 10(-10)). Imputation and fine-mapping analyses were performed in these two regions for a subset of 5551 bladder cancer cases and 10 242 controls. Analyses at the 13q34 region suggest a single signal marked by rs4907479. In contrast, we detected two signals in the 20p12.2 region-the first signal is marked by rs6104690, and the second signal is marked by two moderately correlated SNPs (r(2) = 0.53), rs6108803 and the previously reported rs62185668. The second 20p12.2 signal is more strongly associated with the risk of muscle-invasive (T2-T4 stage) compared with non-muscle-invasive (Ta, T1 stage) bladder cancer (case-case P ≤ 0.02 for both rs62185668 and rs6108803). Functional analyses are needed to explore the biological mechanisms underlying these novel genetic associations with risk for bladder cancer.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.